The company has: Generated a proprietary portfolio of more than 40 validated cancer targets Identified multiple product opportunities for MAbs, small molecules and vaccines that access 14 different tumor types Signed a five-year license agreement with Abgenix allowing development of up to 25 fully human MAb products Established a series of proprietary, patient-derived xenograft mouse models to facilitate discovery of targets and validation of targets and products Signed a license and collaboration deal with Genentech covering two targets and related MAbs for the development of therapeutic and diagnostic products Generated a large patent portfolio including 28 issued patents, 18 allowed, and over 250 pending patent applications Commissioned a clinical-scale antibody manufacturing facility Invented DeRace, a proprietary proteomics technology